Kanghua Biotechnology: Nameixin has completed the first phase of business registration changes, with a registered capital of 27.17 million yuan.

Kanghua Biotechnology announced that on April 29, 2026, the company will hold an extraordinary shareholders' meeting to review and approve the proposals for external investment and related transactions, intending to subscribe to the new registered capital of Nameixin in installments and acquire equity, with a goal of holding 100% equity in Nameixin after the transaction is completed. Recently, Nameixin has completed the business registration procedures for the first phase of this transaction and has obtained a "Business License" issued by the Market Supervision Administration of the China Free Trade Pilot Zone, with a registered capital of 27.17 million yuan. The company will fulfill its information disclosure obligations in a timely manner based on further developments.